AR105401A1 - Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento - Google Patents
Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimientoInfo
- Publication number
- AR105401A1 AR105401A1 ARP160102193A ARP160102193A AR105401A1 AR 105401 A1 AR105401 A1 AR 105401A1 AR P160102193 A ARP160102193 A AR P160102193A AR P160102193 A ARP160102193 A AR P160102193A AR 105401 A1 AR105401 A1 AR 105401A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenoviral vector
- liofilized
- mixting
- waterproof
- procedure
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 241000282575 Gorilla Species 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 241000282576 Pan paniscus Species 0.000 abstract 1
- 241000282577 Pan troglodytes Species 0.000 abstract 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una mezcla acuosa que comprende un vector adenoviral, un crioprotector que es un azúcar amorfo seleccionado de trehalosa, sacarosa, lactosa, rafinosa, dextrano, manitol y combinaciones de los mismos, y cloruro de sodio en una cantidad entre cero y 50 mM. Reivindicación 11: Una mezcla de acuerdo con cualquiera de las reivindicaciones anteriores, en la que el vector adenoviral es un vector adenoviral de simio no humano, tal como un vector adenoviral de chimpancé, un vector adenoviral de bonobo o un vector adenoviral de gorila. Reivindicación 30: Una mezcla de acuerdo con cualquiera de las reivindicaciones anteriores, en la que el vector adenoviral comprende un transgén que es un transgén inmunogénico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513010.7A GB201513010D0 (en) | 2015-07-23 | 2015-07-23 | Novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105401A1 true AR105401A1 (es) | 2017-09-27 |
Family
ID=54106515
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102193A AR105401A1 (es) | 2015-07-23 | 2016-07-20 | Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento |
| ARP210100121A AR121079A2 (es) | 2015-07-23 | 2021-01-20 | Formulación |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100121A AR121079A2 (es) | 2015-07-23 | 2021-01-20 | Formulación |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10722470B2 (es) |
| EP (1) | EP3325016B1 (es) |
| JP (1) | JP6797891B2 (es) |
| CN (1) | CN108025081B (es) |
| AR (2) | AR105401A1 (es) |
| BE (1) | BE1023537B1 (es) |
| BR (1) | BR112018001260A2 (es) |
| CA (1) | CA2992922A1 (es) |
| GB (1) | GB201513010D0 (es) |
| MX (1) | MX2018001006A (es) |
| WO (1) | WO2017013169A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11047534B2 (en) | 2016-01-28 | 2021-06-29 | EcoSense Lighting, Inc. | Multizone mixing cup illumination system |
| MX2020003385A (es) * | 2017-10-16 | 2020-10-01 | Glaxosmithkline Biologicals Sa | Vectores adenovirales de replicacion competente. |
| AU2018378590A1 (en) * | 2017-12-05 | 2020-06-25 | Beacon Therapeutics Limited | Formulation optimization for viral particles |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| ES2966060T3 (es) * | 2018-04-20 | 2024-04-18 | Laboratorio Reig Jofre S A | Composiciones estables de adenovirus |
| EP3587581A1 (en) * | 2018-06-26 | 2020-01-01 | GlaxoSmithKline Biologicals S.A. | Formulations for simian adenoviral vectors having enhanced storage stability |
| CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CR20220129A (es) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Vacunas para vhb y métodos de tratamiento de vhb |
| MX2023001411A (es) * | 2020-08-07 | 2023-05-15 | Janssen Biotech Inc | Formulaciones para particulas virales altamente purificadas. |
| WO2022067273A1 (en) * | 2020-09-24 | 2022-03-31 | Nant Holdings Ip, Llc | Vaccine compositions for mucosal immune response |
| CA3198538A1 (en) * | 2020-11-16 | 2022-05-19 | Bakul Subodh BHATNAGAR | Enhanced formulation stabilization and improved lyophilization processes |
| CN114903922B (zh) * | 2021-02-09 | 2024-04-26 | 武汉博沃生物科技有限公司 | 包含腺病毒的医药配制品及其保存方法 |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| TW202426017A (zh) * | 2022-11-24 | 2024-07-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 非包膜病毒的藥物組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| CA2553541C (en) * | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
| ATE476967T1 (de) * | 2004-08-12 | 2010-08-15 | Schering Corp | Stabile pegylierte interferon-formulierung |
| AU2006318583A1 (en) | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| CN1883707A (zh) * | 2006-05-19 | 2006-12-27 | 吉林大学 | 重组腺病毒的冻干制剂及其制备方法 |
| KR101943429B1 (ko) * | 2010-03-31 | 2019-01-29 | 스타빌리테크 리미티드 | 바이러스 입자, 폴리펩타이드 또는 생물학적 물질의 안정화를 위한 부형제 |
| WO2012075376A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| SG11201405228VA (en) | 2012-03-12 | 2014-11-27 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
| WO2015040234A1 (en) * | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| GB201701239D0 (en) * | 2017-01-25 | 2017-03-08 | Glaxosmithkline Biologicals Sa | Novel formulation |
-
2015
- 2015-07-23 GB GBGB1513010.7A patent/GB201513010D0/en not_active Ceased
-
2016
- 2016-07-20 WO PCT/EP2016/067280 patent/WO2017013169A1/en active Application Filing
- 2016-07-20 JP JP2018503207A patent/JP6797891B2/ja active Active
- 2016-07-20 CN CN201680054923.2A patent/CN108025081B/zh active Active
- 2016-07-20 AR ARP160102193A patent/AR105401A1/es unknown
- 2016-07-20 EP EP16751192.2A patent/EP3325016B1/en active Active
- 2016-07-20 CA CA2992922A patent/CA2992922A1/en active Pending
- 2016-07-20 BR BR112018001260A patent/BR112018001260A2/pt not_active IP Right Cessation
- 2016-07-20 MX MX2018001006A patent/MX2018001006A/es unknown
- 2016-07-20 US US15/746,473 patent/US10722470B2/en active Active
- 2016-07-20 BE BE2016/5605A patent/BE1023537B1/fr not_active IP Right Cessation
-
2021
- 2021-01-20 AR ARP210100121A patent/AR121079A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE1023537A1 (fr) | 2017-04-26 |
| US10722470B2 (en) | 2020-07-28 |
| EP3325016C0 (en) | 2023-12-20 |
| EP3325016A1 (en) | 2018-05-30 |
| CN108025081B (zh) | 2021-11-02 |
| AR121079A2 (es) | 2022-04-13 |
| WO2017013169A1 (en) | 2017-01-26 |
| MX2018001006A (es) | 2018-06-06 |
| GB201513010D0 (en) | 2015-09-09 |
| JP6797891B2 (ja) | 2020-12-09 |
| EP3325016B1 (en) | 2023-12-20 |
| US20180214379A1 (en) | 2018-08-02 |
| BR112018001260A2 (pt) | 2018-09-11 |
| CN108025081A (zh) | 2018-05-11 |
| CA2992922A1 (en) | 2017-01-26 |
| JP2018521078A (ja) | 2018-08-02 |
| BE1023537B1 (fr) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105401A1 (es) | Mezcla acuosa que comprende un vector adenoviral, composición liofilizada, procedimiento | |
| UY35281A (es) | Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos | |
| BR112015012161A8 (pt) | agente de crioproteção e seu uso, composições de crioproteção e método para criopreservar amostra". | |
| EA201691911A1 (ru) | Быстродействующие композиции инсулина | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| CO2017001902A2 (es) | Adyuvantes acondicionadores del agua que promueven una baja volatilidad | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| BR112017026666A2 (pt) | armazenagem de longo prazo e conservação de plaquetas | |
| AR101783A1 (es) | Concepto de empalme de audio | |
| BR112017004925A2 (pt) | composição e método | |
| WO2017062879A3 (en) | Dosing regimens | |
| BR112015028824A2 (pt) | composição de tensoativo concentrada | |
| MX2019003212A (es) | Composiciones que comprenden tensioactivos especificos y altos niveles de glicerina. | |
| CL2020000069A1 (es) | Mejora de las características del suelo con compuestos lactobionatos. | |
| CL2017001039A1 (es) | Composiciones anti-transpirantes anhidras | |
| CL2017000663A1 (es) | Uso de compuestos heterocíclicos fluoroalquenil sulfano para repeler moluscos | |
| AR086672A1 (es) | Formulaciones de furina recombinante | |
| BR112016028585A2 (pt) | composições herbicidas sólidas contendo um agente de proteção | |
| MX365973B (es) | Barras de limpieza con taurina. | |
| UY37282A (es) | Composiciones protectoras de aminopiralida en especies de brassica con clopiralida y métodos para su uso | |
| BR112016028662A2 (pt) | composições herbicidas sólidas contendo um agente de proteção | |
| BR112016028368A2 (pt) | composições herbicidas sólidas contendo um agente de proteção | |
| CL2015002971A1 (es) | Composición biofarmacológica que comprende componentes producidos y/o secretados por células troncales mesenquimales (msc), que permite recuperar la capacidad regenerativa tisular, en una situación de esteatosis hepática, o donde la capacidad de regeneración endógena del tejido hepático se encuentra inhibida | |
| GR1008713B (el) | Μεθοδος και συστημα πυροσβεσης με τη χρηση ελικοπτερων | |
| AR108350A1 (es) | Solución buffer para mantener y conservar adn, usos y kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |